Research & Development
Metabolon to participate in study to identify metabolomic biomarkers for Parkinson’s disease
Metabolon said that it will participate in a UK-based longitudinal study to identify biomarkers that may contribute to an understanding the progression of Parkinson’s disease.
November 15, 2022
Qiagen, Neuron23 to develop CDx for Parkinson’s
Under the agreement, Qiagen will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson's disease to a LRRK2 inhibitor.
September 13, 2022
Labcorp NfL test confirms neurodegenerative disease
The neurofilament light chain (NfL) blood test will allow doctors to identify and verify signs of neurodegenerative disease, enabling physicians to provide a more effective and efficient path to diagnosis and treatment for patients, the firm said.
July 12, 2022
PreciseDx touts AI software for early detection of Parkinson's
PreciseDx's AI morphology feature array was used for the immunohistochemical detection of α-synuclein within peripheral nerves of salivary glands. The algorithm also used quantitative feature extraction based on morphology features to accurately distinguish Lewy-type synucleinopathy in early-stage Parkinson's disease biopsy specimens, according to the study, which was recently published in Acta Neuropathologica Communications.
April 19, 2022
Lifespin establishes division in the U.S.
Lifespin is a deep learning company that is building a diagnostic testing platform based on metabolomics. The company's U.S. subsidiary is incorporated in Delaware and initially based in Boston. Dr. Ali Tinazli, the president and CEO of Lifespin, and Dr. Trevor Hawkins, a Lifespin board member, will lead the operations in the U.S.
April 13, 2022
Insightec to launch new trials of Exablate Neuro
One study will evaluate the use of Exablate Neuro to treat patients with primary non-small cell lung cancer that has metastasized to the brain in conjunction with Keytruda, a humanized antibody immunotherapy. Exablate Neuro could be used to open up the blood-brain barrier to make immunotherapy agents like Keytruda more effective.
March 9, 2022
Experts seek consensus on genes to include in Parkinson's tests
"Our findings highlight the urgent need for expert opinion on which genes and variants commercial laboratory services should consider for general PD panels and other PD-related panels," wrote the research group, led by Lola Cook of Indiana University.
October 27, 2021
BrainChip, NaNose laud progress in breath sample COVID-19 test
The test incorporates NaNose Medical's sensor array to collect data and BrainChip's Akida artificial intelligence chip to perform the diagnosis, according to the two firms. NaNose's sensory array is based on technology developed at Technion Israel Institute of Technology in Haifa, and has similar sensitivity to minute quantities of volatile organic compounds (VOCs) as a dog's nose.
February 24, 2021
Parkinson's Foundation demonstrates role of genetic testing in pilot study
The study offered free genetic testing of clinically relevant Parkinson's-related genes and free genetic counseling to help participants better understand their results. The preliminary findings demonstrated the feasibility of conducting comprehensive genetic testing and genetic counseling for the disease and identified rare genetic mutation carriers linked to the disease.
July 7, 2020
Alpha-synuclein saliva biomarker for Parkinson's not ready for prime time
Researchers at the University of Athens evaluated the use of salivary α-Syn as a diagnostic marker in eight trials including a total of 1,240 patients identified through a systematic review of 476 studies. They found different results depending on the way α-Syn was measured -- total α-Syn versus oligomeric salivary α-Syn.
August 18, 2019
Parkinson's Foundation kicks off genetic testing program
The program -- dubbed PD GENEration -- will kick off at Columbia University Irving Medical Center, but other pilot sites will come on board later. Results will be stored and used for research purposes. The plan is to initially offer the testing program to 600 participants, and later roll it out to U.S. 50 centers by 2020; the foundation's long-term aim is to include 15,000 Parkinson's patients.
July 15, 2019
Cerebrospinal fluid test helps pinpoint dementia disorders
The meta-analysis of studies involving about 10,000 people with neurological disorders showed that neurofilament light protein as measured with a commercially available immunoassay was elevated for people with neurological and psychiatric conditions. Results were broadly similar; however, frontotemporal dementia and HIV-related cognitive decline were differentiated from other dementias, and Parkinson's disease was differentiated from atypical parkinsonian conditions.
June 17, 2019
Page 1 of 1